Efalizumab Lifts Quality of Life in Just Two Weeks

November 15, 2002

Winston-Salem, N.C. - After subcutaneous treatment with efalizumab(Raptiva), patients who achieved 50 to 75 percent improvement in PsoriasisArea and Severity Index (PASI) score reported improvement in quality oflife.